JTE-051
As of the edition of 20 October 2026, JTE-051 is a drug known only by a code name: stopped in 2018; acts on ITK.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2018
- Kind
- Code name only
- Registered trials
- 2, 1 stopped early
- Disease areas
- Skin and connective tissue; Bones, joints and muscles; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of JTE-051.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ITK | Tyrosine-protein kinase ITK/TSK | Q08881 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 1 | 0 | 1 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Akros Pharma | Lead sponsor of trials | 2016 to now |